All In Biotech

Drug Trial Radar · NCT05146219

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

A Phase II, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of TY-9591 Tablets in Patients With EGFR-Mutated Non-small Cell Lung Cancer With Brain or Leptomeningeal Metastases

Last checked: Nov 19, 2026Latest source record: Dec 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

29

Actual

Start

Apr 2, 2022

Primary completion

Mar 21, 2024

Study completion Nov 13, 2024

Sponsor

Lead sponsor
TYK Medicines, IncIndustry
Sponsor type
Industry
First posted
Dec 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of TY-9591 tablets in the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with brain or leptomeningeal metastases.

Conditions

  • NSCLC
  • EGFR Activating Mutation
  • Brain Metastases
  • Leptomeningeal Metastasis

Interventions

  • TY-9591 TabletsDrug

    TY-9591 Tablets 160mg/d

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intracranial Overall Response Rate (iORR)Time frame: 13 months.
  2. Extracranial Overall Response Rate (eORR)Time frame: 13 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.